HuGE Literature Finder
Records
1
-
30
| Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 2023 2 14 (1): 1071. Chmielecki Juliann, Mok Tony, Wu Yi-Long, Han Ji-Youn, Ahn Myung-Ju, Ramalingam Suresh S, John Thomas, Okamoto Isamu, Yang James Chih-Hsin, Shepherd Frances A, Bulusu Krishna C, Laus Gianluca, Collins Barbara, Barrett J Carl, Hartmaier Ryan J, Papadimitrakopoulou Vassili |
| Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European journal of cancer (Oxford, England : 1990) 2023 2 183 38-48. Bylicki Olivier, Tomasini Pascale, Radj Gervais, Guisier Florian, Monnet Isabelle, Ricordel Charles, Bigay-Game Laurence, Geier Margaux, Chouaid Christos, Daniel Catherine, Swalduz Aurelie, Toffart Anne-Claire, Doubre Helene, Peloni Jean-Michel, Moreau Diane, Subtil Fabien, Grellard Jean-Michel, Castera Marie, Clarisse Benedicte, Martins-Lavinas Pedro-Henrique, Decroisette Chantal, Greillier Laurent, |
| Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 2023 2 14 (1): 1070. Chmielecki Juliann, Gray Jhanelle E, Cheng Ying, Ohe Yuichiro, Imamura Fumio, Cho Byoung Chul, Lin Meng-Chih, Majem Margarita, Shah Riyaz, Rukazenkov Yuri, Todd Alexander, Markovets Aleksandra, Barrett J Carl, Hartmaier Ryan J, Ramalingam Suresh |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
| Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. Clinical lung cancer 2023 1 . Chen Minjiang, Xu Yan, Zhao Jing, Liu Xiaoyan, Liu Xiangning, Zhang Dongming, Shi Yuequan, Zhang Li, Zhong Wei, Wang Mengzh |
| Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report. Medicine 2023 1 101 (49): e31875. Zhao Nan, Xin Hua, Qin Changjuan, Li Zhiqi, Sun Hongb |
| Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clinical journal of the American Society of Nephrology : CJASN 2023 2 18 (3): 344-355. Kallash Mahmoud, Wang Yujie, Smith Abigail, Trachtman Howard, Gbadegesin Rasheed, Nester Carla, Canetta Pietro, Wang Chen, Hunley Tracy E, Sperati C John, Selewski David, Ayoub Isabelle, Srivastava Tarak, Mottl Amy K, Kopp Jeffrey, Gillespie Brenda, Robinson Bruce, Chen Dhruti, Steinke Julia, Twombley Katherine, Reidy Kimberly, Mucha Krzysztof, Greenbaum Larry A, Blazius Brooke, Helmuth Margaret, Yonatan Peleg, Parekh Rulan S, Hogan Susan, Royal Virginie, D'Agati Vivette, Chishti Aftab, Falk Ronald, Gharavi Ali, Holzman Lawrence, Klein Jon, Smoyer William, Kretzler Matthias, Gipson Debbie, Kidd Jason M, |
| Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC medicine 2023 1 21 (1): 11. Shi Yuankai, Zhou Jianying, Zhao Yanqiu, Zhu Bo, Zhang Liangming, Li Xingya, Fang Jian, Shi Jianhua, Zhuang Zhixiang, Yang Sheng, Wang Donglin, Yu Huiqing, Zhang Longzhen, Zheng Rongsheng, Greco Michael, Wang Tingti |
| Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 Sep 25 (9): 651-657. Zhang Guowei, Cheng Ruirui, Niu Yuanyuan, Wang Huijuan, Yan Xiangtao, Zhang Mina, Zhang Xiaojuan, Yang Jinpo, Wei Chunhua, Ma Zhiyo |
| Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer. Cancer research and treatment 2022 Aug . Lee Jang Ho, Kim Eun Young, Park Cheol-Kyu, Lee Shin Yup, Lee Min Ki, Yoon Seong-Hoon, Lee Jeong Eun, Lee Sang Hoon, Kim Seung Joon, Lee Sung Yong, Lim Jun Hyeok, Jang Tae-Won, Jang Seung Hun, Lee Kye Young, Lee Seung Hyeun, Yang Sei Hoon, Park Dong Won, Park Chan Kwon, Kang Hye Seon, Yeo Chang Dong, Choi Chang-Min, Lee Jae Che |
| A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thoracic cancer 2022 Jun 13 (12): 1827-1836. Asami Kazuhiro, Ando Masahiko, Nishimura Takashi, Yokoi Takashi, Tamura Atsuhisa, Minato Koichi, Mori Masahide, Ogushi Fumitaka, Yamamoto Akiyoshi, Yoshioka Hiroshige, Kawahara Masaaki, Atagi Shin |
| A Targeted Next-Generation Sequencing Panel to Genotype Gliomas. Life (Basel, Switzerland) 2022 Jun 12 (7): . Guarnaccia Maria, Guarnaccia Laura, La Cognata Valentina, Navone Stefania Elena, Campanella Rolando, Ampollini Antonella, Locatelli Marco, Miozzo Monica, Marfia Giovanni, Cavallaro Sebastia |
| Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Jun . Lu Shun, Zhang Yiping, Zhang Guojun, Zhou Jianying, Cang Shundong, Cheng Ying, Wu Gang, Cao Peiguo, Lv Dongqing, Jian Hong, Chen Chengshui, Jin Xiangming, Tian Panwen, Wang Kai, Jiang Guanming, Chen Gongyan, Chen Qun, Zhao Hui, Ding Cuimin, Guo Renhua, Sun Guoping, Wang Bin, Jiang Liyan, Liu Zhe, Fang Jian, Yang Junquan, Zhuang Wu, Liu Yunpeng, Zhang Jian, Pan Yueyin, Chen Jun, Yu Qitao, Zhao Min, Cui Jiuwei, Li Dianming, Yi Tienan, Yu Zhuang, Yang Yan, Zhang Yan, Zhi Xiuyi, Huang Yunchao, Wu Rong, Chen Liangan, Zang Aimin, Cao Lejie, Li Qingshan, Li Xiaoling, Song Yong, Wang Donglin, Zhang Shucai, Ding Lieming, Zhang Ling, Yuan Xiaobin, Yao Lin, Shen Zhil |
| Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. The Lancet. Respiratory medicine 2022 Jun . Shi Yuankai, Chen Gongyan, Wang Xiang, Liu Yunpeng, Wu Lin, Hao Yanrong, Liu Chunling, Zhu Shuyang, Zhang Xiaodong, Li Yuping, Liu Jiwei, Cao Lejie, Cheng Ying, Zhao Hui, Zhang Shucai, Zang Aimin, Cui Jiuwei, Feng Jian, Yang Nong, Liu Fei, Jiang Yong, Gu Chuan, |
| Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. Kidney international 2022 Jun . Gorski Mathias, Rasheed Humaira, Teumer Alexander, Thomas Laurent F, Graham Sarah E, Sveinbjornsson Gardar, Winkler Thomas W, Günther Felix, Stark Klaus J, Chai Jin-Fang, Tayo Bamidele O, Wuttke Matthias, Li Yong, Tin Adrienne, Ahluwalia Tarunveer S, Ärnlöv Johan, Åsvold Bjørn Olav, Bakker Stephan J L, Banas Bernhard, Bansal Nisha, Biggs Mary L, Biino Ginevra, Böhnke Michael, Boerwinkle Eric, Bottinger Erwin P, Brenner Hermann, Brumpton Ben, Carroll Robert J, Chaker Layal, Chalmers John, Chee Miao-Li, Chee Miao-Ling, Cheng Ching-Yu, Chu Audrey Y, Ciullo Marina, Cocca Massimiliano, Cook James P, Coresh Josef, Cusi Daniele, de Borst Martin H, Degenhardt Frauke, Eckardt Kai-Uwe, Endlich Karlhans, Evans Michele K, Feitosa Mary F, Franke Andre, Freitag-Wolf Sandra, Fuchsberger Christian, Gampawar Piyush, Gansevoort Ron T, Ghanbari Mohsen, Ghasemi Sahar, Giedraitis Vilmantas, Gieger Christian, Gudbjartsson Daniel F, Hallan Stein, Hamet Pavel, Hishida Asahi, Ho Kevin, Hofer Edith, Holleczek Bernd, Holm Hilma, Hoppmann Anselm, Horn Katrin, Hutri-Kähönen Nina, Hveem Kristian, Hwang Shih-Jen, Ikram M Arfan, Josyula Navya Shilpa, Jung Bettina, Kähönen Mika, Karabegovi? Irma, Khor Chiea-Chuen, Koenig Wolfgang, Kramer Holly, Krämer Bernhard K, Kühnel Brigitte, Kuusisto Johanna, Laakso Markku, Lange Leslie A, Lehtimäki Terho, Li Man, Lieb Wolfgang, , Lind Lars, Lindgren Cecilia M, Loos Ruth J F, Lukas Mary Ann, Lyytikäinen Leo-Pekka, Mahajan Anubha, Matias-Garcia Pamela R, Meisinger Christa, Meitinger Thomas, Melander Olle, Milaneschi Yuri, Mishra Pashupati P, Mononen Nina, Morris Andrew P, Mychaleckyj Josyf C, Nadkarni Girish N, Naito Mariko, Nakatochi Masahiro, Nalls Mike A, Nauck Matthias, Nikus Kjell, Ning Boting, Nolte Ilja M, Nutile Teresa, O'Donoghue Michelle L, O'Connell Jeffrey, Olafsson Isleifur, Orho-Melander Marju, Parsa Afshin, Pendergrass Sarah A, Penninx Brenda W J H, Pirastu Mario, Preuss Michael H, Psaty Bruce M, Raffield Laura M, Raitakari Olli T, Rheinberger Myriam, Rice Kenneth M, Rizzi Federica, Rosenkranz Alexander R, Rossing Peter, Rotter Jerome I, Ruggiero Daniela, Ryan Kathleen A, Sabanayagam Charumathi, Salvi Erika, Schmidt Helena, Schmidt Reinhold, Scholz Markus, Schöttker Ben, Schulz Christina-Alexandra, Sedaghat Sanaz, Shaffer Christian M, Sieber Karsten B, Sim Xueling, Sims Mario, Snieder Harold, Stanzick Kira J, Thorsteinsdottir Unnur, Stocker Hannah, Strauch Konstantin, Stringham Heather M, Sulem Patrick, Szymczak Silke, Taylor Kent D, Thio Chris H L, Tremblay Johanne, Vaccargiu Simona, van der Harst Pim, van der Most Peter J, Verweij Niek, Völker Uwe, Wakai Kenji, Waldenberger Melanie, Wallentin Lars, Wallner Stefan, Wang Judy, Waterworth Dawn M, White Harvey D, Willer Cristen J, Wong Tien-Yin, Woodward Mark, Yang Qiong, Yerges-Armstrong Laura M, Zimmermann Martina, Zonderman Alan B, Bergler Tobias, Stefansson Kari, Böger Carsten A, Pattaro Cristian, Köttgen Anna, Kronenberg Florian, Heid Iris |
| Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. European journal of cancer (Oxford, England : 1990) 2022 May 170 64-72. Rossini Daniele, Germani Marco M, Lonardi Sara, Pietrantonio Filippo, Dell'Aquila Emanuela, Borelli Beatrice, Allegrini Giacomo, Maddalena Giulia, Randon Giovanni, Marmorino Federica, Zaniboni Alberto, Buonadonna Angela, Boccaccino Alessandra, Conca Veronica, Antoniotti Carlotta, Passardi Alessandro, Masi Gianluca, Cremolini Chia |
| A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. JTO clinical and research reports 2022 11 3 (12): 100416. Lai Gillianne G Y, Yeo Jia Chi, Jain Amit, Zhou Siqin, Pang Mengyuan, Alvarez Jacob J S, Sim Ngak Leng, Tan Aaron C, Suteja Lisda, Lim Tze Wei, Guo Yu Amanda, Shen Meixin, Saw Stephanie P L, Rohatgi Neha, Yeong Joe P S, Takano Angela, Lim Kiat Hon, Gogna Apoorva, Too Chow Wei, Da Zhuang Kun, Tan Wan Ling, Kanesvaran Ravindran, Ng Quan Sing, Ang Mei Kim, Rajasekaran Tanujaa, Wang Lanying, Toh Chee Keong, Lim Wan-Teck, Tam Wai Leong, Tan Sze Huey, Skanderup Anders M J, Tan Eng-Huat, Tan Daniel S |
| Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations. Clinical journal of the American Society of Nephrology : CJASN 2022 5 17 (6): 798-808. Brandenburg Jean-Tristan, Govender Melanie A, Winkler Cheryl A, Boua Palwende Romuald, Agongo Godfred, Fabian June, Ramsay Michè |
| Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thoracic cancer 2022 4 13 (10): 1471-1478. Tanaka Hisashi, Sakamoto Hiroaki, Akita Takahiro, Ohyanagi Fumiyoshi, Kawashima Yosuke, Tambo Yuichi, Tanimoto Azusa, Horiike Atsushi, Miyauchi Eisaku, Tsuchiya-Kawano Yuko, Yanagitani Noriko, Nishio Mako |
| Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study. Therapeutic advances in medical oncology 2022 7 14 17588359221113278. Lee Suey-Haur, Lin Yu-Ching, Chiu Li-Chung, Ju Jia-Shiuan, Tung Pi-Hung, Huang Allen Chung-Cheng, Li Shih-Hong, Fang Yueh-Fu, Chen Chih-Hung, Kuo Scott Chih-Hsi, Wang Chin-Chou, Yang Cheng-Ta, Hsu Ping-Ch |
| Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. Frontiers in oncology 2022 12 985284. Jiang Meilin, Yang Pei, Li Jing, Peng Wenying, Pu Xingxiang, Chen Bolin, Li Jia, Wang Jingyi, Wu L |
| Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial. JAMA oncology 2022 7 8 (9): 1328-1332. Xu Jiachen, Liu Zheng, Bai Hua, Dong Guilan, Zhong Jia, Wan Rui, Zang Aiming, Li Xiaoling, Li Qingshan, Guo Jun, Du Nan, Zhong Diansheng, Huang Yan, Lv Qun, Zhang Jinghua, Zhao Yue, Gao Liming, Li Lin, Zhang Chunyi, Zhao Jun, Li Baolan, Liu Zhe, Yang Zhenlin, Ji Dong, Wang Tao, Duan Jianchun, Wang Zhijie, Wang J |
| Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA. OncoTargets and therapy 2022 5 15 571-584. Li Jie, Chen Siwen, Xue Hui, Wang Haoyi, Huang Tianwei, Xie Hongya, He Jiang, Ke Cai, Yu Zhaonan, Ni B |
| Identifying Genetic Variants and Metabolites Associated with Rapid Estimated Glomerular Filtration Rate Decline in Korea Based on Genome-Metabolomic Integrative Analysis. Metabolites 2022 11 12 (11): . Lee Sangjun, Han Miyeun, Moon Sungji, Kim Kyungsik, An Woo Ju, Ryu Hyunjin, Oh Kook-Hwan, Park Sue |
| Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study. BMC cancer 2022 10 22 (1): 1035. Fujii Hiroaki, Nagakura Hideyuki, Kobayashi Nobuaki, Kubo Sousuke, Tanaka Katsushi, Watanabe Keisuke, Horita Nobuyuki, Hara Yu, Nishikawa Masanori, Miura Kenji, Koizumi Harumi, Ito Yu, Tsubakihara Motofumi, Miyazawa Naoki, Kudo Makoto, Shinkai Masaharu, Kaneko Takes |
| Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors. Therapeutic advances in medical oncology 2022 6 14 17588359221105022. Xu Ting, Wang Xicheng, Wang Zhenghang, Deng Ting, Qi Changsong, Liu Dan, Li Yanyan, Ji Congcong, Li Jian, Shen L |
| PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. Journal of cancer research and clinical oncology 2022 7 148 (12): 3557-3566. Zhu Yixiang, Zhang Ye, Hu Xingsheng, Wang Mingzhao, Wang Hongyu, Liu Yut |
| Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO open 2022 5 7 (3): 100473. Xing P, Zheng X, Wang Y, Chu T, Wang S, Jiang J, Qian J, Han X, Ding L, Wang Y, Cui L, Li H, Li L, Chen X, Han B, Hu P, Shi |
| Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. Thoracic cancer 2022 6 13 (14): 2057-2063. Kwok Wang Chun, Ho James Chung Man, Tam Terence Chi Chun, Ip Mary Sau Man, Lam David Chi Leu |
| The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study. Cancer medicine 2022 11 . Yu Xiaoqing, Si Jinfei, Wei Jingwen, Wang Yanling, Sun Yan, Jin Jianan, Zhang Xiaoyan, Ma Tonghui, Song Zheng |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 29, 2023
- Content source: